Clinical AI may improve care, but it has to meet high standards of evidence and patient safety before it is relied on.
KEY QUESTION
Can AI help clinicians provide better care, and who checks its output?
Priorities are editorial judgements by Cyprus AI Monitor about public value and the attention each sector needs. They are not official strategy rankings, readiness scores or EU AI Act risk categories.
A clinician-reviewed draft of routine notes could reduce paperwork and leave more time for a consultation.
These are examples of possible uses. They do not describe systems already in use or promise any benefit.
Test on the intended patient population. Protect health data, record errors and keep accountable clinical oversight. Do not treat a working digital health portal as evidence that clinical AI is safe.
Published figures for Cyprus. These supplementary measures are not part of the index score.
78.75/100
Observation period:
EU average · 2025: 86.51/100
Composite maturity score for people’s technical access to electronic health records.
The score describes the access that is technically available. How many patients use the service, how widely clinicians use AI and the quality of treatment are outside its scope.
€10.5 million
Observation period:
R&D expenditure classified under medical sciences.
Includes research in every field, not only AI, in the government-controlled areas of Cyprus. Spending alone does not show whether research led to successful products or public benefit.
What we still need to know
This release includes no verified Cyprus-wide measure of clinical AI use, patient benefit or error rates.
Proposed measures for future data collection. No values have been published for them.
Related source
The 2026 eHealth study measures technical access to records. It explains what its maturity score can and cannot establish.
Source or service page · checked 12 Sept 2026